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LETTER TO THE EDITOR
Constitutional frequency of rare alleles of c-Ha-ras in breast cancer
patients
Sir - Wyllie et al (1988) in a recent issue suggest, from their
observations of c-Ha-ras restriction fragment length
polymorphisms (RFLPs) in colorectal cancer, that the
extremely high constitutional incidence of rare alleles in
breast cancer patients (41% compared with a control value
of 9%) found by Lidereau et al (1986), may have resulted
from technical difficulties. We would like to support this
suggestion by presenting our own results of c-Ha-ras RFLPs
in 80 breast cancer patients (Table I).
Table I Allele distribution of c-Ha-ras in 80 breast cancer patients
compared with our control group of 101 (Heighway et al., 1986). All
assays were done on peripheral blood samples. The figures in
brackets are percentages
Allele type
al a2 a3 a4 Rare Total
Control 120(60) 32(16) 26(13) 15(7) 9(4) 202
Breast Cancer
Patients 95(59) 19(12) 23(14) 18(11) 5(3) 160
These results show no significant difference in rare allele
frequencies between controls and patients (X2=0.143,
P=0.706). Although there is a relative increase in a4 alleles
in breast cancer patients this is not significant (X2= 1.148,
P=0.284) whereas we previously found a significant increase
in patients with non-small cell carcinoma of the lung
(Heighway et al., 1986). Wyllie et al. (1988) showed that the
sum of a3 and a4 alleles in colorectal cancer patients was
significantly higher than in controls but this was not the case
for the breast cancer patients in our study (X2= 1.158,
P=0.282).
The problem of migration deviation in Southern blot
analysis is stressed by Wyllie et al. (1988) and we too have
observed a slight shift in allele position in tumour samples
when comparing tumour and peripheral blood DNA.
Tumour DNA is often more impure and may be slightly
degraded when compared to that obtained from peripheral
blood samples. This could result in either partial digests or
unbalanced DNA loadings at a particular position in a gel
causing a band to appear at a slightly different molecular
weight. In the study of Lidereau et al. (1986) for 64 of 104
breast cancer patients, only tumour material was available,
whereas the control data were of course obtained entirely
from the analysis of peripheral blood samples. In our study,
determination of allele frequencies of controls and breast
cancer patients was always from blood samples and in
approximately 80% of patients tumour material was also
available for comparison.
Although certain c-Ha-ras alleles may cause predisposition
to some cancers, our evidence to date suggests that this is
not the case in breast cancer.
Yours etc.,
G.R.M. White', J. Heighway', G.T. Williams2 & D. Scott'
'Paterson Institute for Cancer Research
and 2Medical Oncology,
Christie Hospital and Holt Radium Institute,
Wilmslow Road,
Manchester M20 9BX, UK.
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